Share on StockTwits

The Medicines Company (NASDAQ:MDCO)‘s stock had its “neutral” rating restated by Zacks in a report issued on Thursday. They currently have a $28.00 price objective on the stock. Zacks‘s price objective suggests a potential upside of 8.15% from the company’s current price.

Zacks’ analyst wrote, “The Medicines Co.’s second quarter EPS of $0.18 per share was below the year-earlier EPS of $0.44. Revenues rose 6.3% year over year to $183.8 million, but missed the Zacks Consensus Estimate of $185 million. Although Angiomax should continue growing, we remain concerned about the earlier-than-expected entry of generics. Meanwhile, we are encouraged to see that management is actively pursuing in-licensing deals and acquisitions to drive long-term growth. We are pleased with the company’s co-promotion deal with AstraZeneca. The Recothrom, ProFibrix and Incline deals also look good to us. The Tenaxis acquisition indicates the company’s efforts to diversify its portfolio and reduce its dependence on Angiomax. Meanwhile, Orbactiv’s recent approval is also a positive. We remain Neutral on the stock.”

Shares of The Medicines Company (NASDAQ:MDCO) traded down 0.93% during mid-day trading on Thursday, hitting $25.69. 206,787 shares of the company’s stock traded hands. The Medicines Company has a one year low of $22.71 and a one year high of $41.28. The stock has a 50-day moving average of $25.58 and a 200-day moving average of $27.53. The company’s market cap is $1.654 billion.

The Medicines Company (NASDAQ:MDCO) last posted its quarterly earnings results on Wednesday, July 23rd. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.02) by $0.06. The company had revenue of $183.80 million for the quarter, compared to the consensus estimate of $183.75 million. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was up 6.4% on a year-over-year basis. Analysts expect that The Medicines Company will post $-0.34 EPS for the current fiscal year.

The Medicines Company, is a pharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the global hospital marketplace.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.